- Home
- ATHA vs BIVI Comparison
ATHA vs BIVI Comparison
Compare ATHA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- BIVI
- Stock Information
- Founded
- ATHA 2011
- BIVI 2013
- Country
- ATHA United States
- BIVI United States
- Employees
- ATHA N/A
- BIVI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- BIVI Health Care
- Exchange
- ATHA Nasdaq
- BIVI Nasdaq
- Market Cap
- ATHA 14.8M
- BIVI 14.2M
- IPO Year
- ATHA 2020
- BIVI N/A
- Fundamental
- Price
- ATHA $4.07
- BIVI $1.97
- Analyst Decision
- ATHA
- BIVI
- Analyst Count
- ATHA 0
- BIVI 0
- Target Price
- ATHA N/A
- BIVI N/A
- AVG Volume (30 Days)
- ATHA 47.2K
- BIVI 258.0K
- Earning Date
- ATHA 11-06-2025
- BIVI 11-12-2025
- Dividend Yield
- ATHA N/A
- BIVI N/A
- EPS Growth
- ATHA N/A
- BIVI N/A
- EPS
- ATHA N/A
- BIVI N/A
- Revenue
- ATHA N/A
- BIVI N/A
- Revenue This Year
- ATHA N/A
- BIVI N/A
- Revenue Next Year
- ATHA N/A
- BIVI N/A
- P/E Ratio
- ATHA N/A
- BIVI N/A
- Revenue Growth
- ATHA N/A
- BIVI N/A
- 52 Week Low
- ATHA $2.20
- BIVI $1.42
- 52 Week High
- ATHA $8.26
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- ATHA 74.28
- BIVI 47.48
- Support Level
- ATHA $4.01
- BIVI $1.86
- Resistance Level
- ATHA $4.59
- BIVI $2.04
- Average True Range (ATR)
- ATHA 0.30
- BIVI 0.12
- MACD
- ATHA -0.05
- BIVI 0.08
- Stochastic Oscillator
- ATHA 47.32
- BIVI 73.33
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.